| RIPK2 Protein |
|---|
| Protein Name | Receptor-Interacting Serine/Threonine-Protein Kinase 2 |
| Gene | [RIPK2](/genes/ripk2) |
| UniProt ID | [O43353](https://www.uniprot.org/uniprot/O43353) |
| PDB ID | 1k3m, 4a2c, 5w5z |
| Molecular Weight | 61 kDa |
| Subcellular Localization | Cytoplasm, Cytoskeleton |
| Protein Family | RIP kinase family |
| Tissue Expression | High in immune cells, brain, spinal cord |
RIPK2 Protein — Receptor-Interacting Serine/Threonine-Protein Kinase 2 is a key mediator of innate immune signaling that plays a critical role in neuroinflammation, a hallmark of neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). RIPK2 transduces signals from NOD1 and NOD2 pattern recognition receptors, leading to NF-κB activation, MAPK signaling, and inflammatory gene expression. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
RIPK2 is a 540-amino acid serine/threonine kinase with distinct structural domains:
graph TD
A["N-Terminus"] --> B["Kinase Domain"]
B --> C["Intermediate Region"]
C --> D["CARD Domain"]
B --> E["Activation Loop"]
B --> F["ATP-Binding Site"]
D --> G["Caspase-2 Recruitment"]
style B fill:#ffcdd2
style D fill:#c8e6c9
- N-terminal kinase domain (1-300 aa): Contains activation loop and ATP-binding site, responsible for catalytic activity
- Intermediate region (300-400 aa): Contains regulatory motifs
- C-terminal CARD domain (400-540 aa): Caspase Recruitment Domain for protein-protein interactions
Key structural features:
- Lacks death domain (unlike RIPK1)
- Contains unique CARD domain for signaling specificity
- Undergoes autophosphorylation upon activation at Ser176
- Kinase domain shows selectivity for RIPK2 over RIPK1 inhibitors
RIPK2 is a master regulator of innate immune signaling with multiple roles in the nervous system:
- NOD receptor signaling: Mediates NOD1/NOD2 inflammatory responses to intracellular bacterial peptides
- NF-κB activation: Triggers pro-inflammatory gene expression (TNF-α, IL-1β, IL-6)
- MAPK signaling: Activates JNK and p38 pathways
- Autophagy regulation: Regulates xenophagy and antibacterial defenses
- T-cell activation: Costimulatory signaling in T-cells
- Microglial surveillance: Maintains baseline microglial activity
- CNS immune homeostasis: Regulates neuroinflammation magnitude
- Injury response: Mediates responses to CNS injury
RIPK2 sits at the intersection of innate immunity and neurodegeneration, with growing evidence for its role in multiple conditions:
In Alzheimer's disease, RIPK2 mediates neuroinflammation through multiple pathways :
- NOD2-RIPK2 signaling: Aβ oligomers activate NOD2 receptors on microglia, triggering RIPK2-dependent NF-κB activation and pro-inflammatory cytokine release
- TLR crosstalk: RIPK2 amplifies TLR-mediated inflammatory responses
- NLRP3 inflammasome synergy: RIPK2 collaborates with NLRP3 to enhance IL-1β processing
- Synaptic dysfunction: Chronic RIPK2 activation contributes to synaptic loss
The kinase activity of RIPK2 is elevated in AD brain tissue, particularly in microglia surrounding amyloid plaques .
RIPK2 contributes to Parkinson's disease pathogenesis through :
- Microglial activation: RIPK2 mediates LPS- and α-synuclein-induced microglial activation
- Dopaminergic neuron vulnerability: RIPK2-dependent inflammation accelerates dopaminergic neuron loss
- NLRP3 inflammasome: RIPK2 activates NLRP3 in PD models
- Blood-brain barrier: RIPK2 contributes to BBB dysfunction
- Multiple sclerosis: RIPK2 is implicated in demyelination and disease progression
- Amyotrophic lateral sclerosis (ALS): Elevated RIPK2 in microglia and astrocytes
- Frontotemporal dementia: RIPK2-mediated inflammation in microglial pathology
- Huntington's disease: RIPK2 contributes to inflammatory responses
flowchart LR
subgraph Extracellular["Extracellular"]
A["Aβ oligomers<br/>α-synuclein<br/>LPS"]
end
subgraph Microglial["Microglial Signaling"]
A --> B["NOD1/NOD2<br/>Receptors"]
B --> C["RIPK2"]
C --> D{"Autophosphorylation<br/>Ser176"}
D --> E["NF-κB Pathway"]
D --> F["MAPK Pathway<br/>JNK/p38"]
D --> G["Autophagy"]
end
subgraph Inflammatory["Inflammatory Response"]
E --> H["TNF-α<br/>IL-1β<br/>IL-6"]
F --> H
G --> I["Xenophagy<br/>Clearance"]
end
subgraph Neurodegenerati["Neurodegeneration"]
H --> J["Chronic<br/>Neuroinflammation"]
J --> K["Synaptic Loss<br/>Neuron Death"]
end
style C fill:#fff9c4999
style J fill:#ff6666
style K fill:#ff0000
RIPK2 is an emerging therapeutic target for neurodegenerative diseases:
- Selectivity challenge: Developing RIPK2-selective inhibitors over RIPK1
- WEHI-345: Preclinical inhibitor showing anti-inflammatory effects
- Glibenclamide: FDA-approved drug with off-target RIPK2 activity
- NOD2-RIPK2 axis modulation: Targeting the upstream activator
- Combination therapy: RIPK2 + NLRP3 or RIPK1 inhibition
- Microglial targeting: Cell-specific delivery
- Peripheral vs CNS: Blood-brain barrier penetration challenges
- Immune suppression risk: Balancing anti-inflammatory effects with infection risk
- Biomarkers: RIPK2 activity markers in CSF
No approved RIPK2-targeted therapies exist for neurodegeneration. Research compounds:
| Compound |
Stage |
Notes |
| WEHI-345 |
Preclinical |
RIPK2 kinase inhibitor |
| 4E1R |
Preclinical |
NOD2-RIPK2 inhibitor |
| Gliclazide |
Approved (diabetes) |
Off-target RIPK2 inhibition |
¶ Safety and Contraindications
Potential concerns for RIPK2-targeted approaches:
- Immunodeficiency: NOD2-RIPK2 pathway is important for immune defense
- Infection risk: Increased susceptibility to intracellular bacteria
- GI inflammation: NOD2-RIPK2 in gut immune function